Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications.
To study the long-term safety and effectiveness of ipratropium bromide nasal spray 0.03% in the treatment of nonallergic perennial rhinitis, we administered this medication for 1 year in an open-label trial involving 285 patients. Our intention was to maintain the highest protocol dose possible to gain a clearer picture of the long-term side effect profile of the compound. Ipratropium bromide was well tolerated with no serious side effects in this patient population. It provided a significant improvement in rhinorrhea throughout the year-long trial; only 17 of 285 patients (6%) were considered treatment failures. There was an improvement in patient quality of life, as well as a substantial reduction in the need for other medications (antihistamines, decongestants, and nasal steroids) used to treat perennial rhinitis symptoms.
Grossman
J
J
Banov
C
C
Boggs
P
P
Bronsky
E A
EA
Dockhorn
R J
RJ
Druce
H
H
Findlay
S R
SR
Georgitis
J W
JW
Hampel
F C
FC
Kaiser
H
H
D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D014663:Nasal Decongestants / Q000627:therapeutic use; D009297:Nasal Mucosa / Q000187:drug effects; D009330:Nebulizers and Vaporizers; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*
D005938:Glucocorticoids; D006634:Histamine H1 Antagonists; D014663:Nasal Decongestants; D009241:Ipratropium